Your browser doesn't support javascript.
loading
The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development.
Patten, P A; Schellekens, H.
Affiliation
  • Patten PA; Maxygen Inc., Redwood City, CA 94063, USA. phil.patten@maxygen.com
Dev Biol (Basel) ; 112: 81-97, 2003.
Article in En | MEDLINE | ID: mdl-12762507
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Biopharmaceutics / Recombinant Proteins / Drug Design Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Dev Biol (Basel) Journal subject: ALERGIA E IMUNOLOGIA Year: 2003 Document type: Article Affiliation country: United States Country of publication: Switzerland
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Biopharmaceutics / Recombinant Proteins / Drug Design Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Dev Biol (Basel) Journal subject: ALERGIA E IMUNOLOGIA Year: 2003 Document type: Article Affiliation country: United States Country of publication: Switzerland